Clinical Trials Logo

Transformed Follicular Lymphoma clinical trials

View clinical trials related to Transformed Follicular Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04450069 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Start date: August 14, 2020
Phase: Phase 1
Study type: Interventional

CLBR001 + SWI019 is an combination investigational immunotherapy being evaluated as a potential treatment for patients diagnosed with B cell malignancies who are refractory or unresponsive to salvage therapy or who cannot be considered for or have progressed after autologous hematopoietic cell transplantation. This first-in-human study will assess the safety and tolerability of CLBR001 + SWI019 and is designed to determine the maximum tolerated dose (MTD) or optimal SWI019 dose (OSD). Patients will be administered a single infusion of CLBR001 cells followed by cycles of SWI019. The study will also assess the pharmacokinetics and pharmacodynamics of CLBR001 + SWI019.